Healthcare entrepreneur GSK Velu is gearing up for a major value-unlocking exercise across his healthcare portfolio, with plans to take four of his key businesses public over the next three years. The companies expected to enter the stock market include diagnostics firm Neuberg Diagnostics, eye care network Maxi Vision, hospital chain Kauvery Hospitals, and medical technology company Trivitron Healthcare.
Advertisement
According to Velu, Neuberg Diagnostics and Maxi Vision are likely to lead the listing pipeline, with potential IPOs targeted for 2027. Kauvery Hospitals could follow, while Trivitron’s public debut may come later after the company completes a significant acquisition and secures another round of private equity investment.
Velu maintains substantial ownership across these businesses, holding full control of Trivitron, a majority stake in Neuberg Diagnostics and Maxi Vision, and a significant shareholding in Kauvery Hospitals. Industry estimates suggest that the combined annual revenue of these enterprises exceeds ₹7,000 crore, with each company potentially achieving a valuation of over $1 billion by the time of listing.
Founded in 1997, Trivitron has grown from a medical devices distribution company into one of India’s leading domestic manufacturers of healthcare technology. The company has established a strong presence in medical imaging, diagnostics, and renal care solutions. Its manufacturing footprint spans multiple facilities across India, along with international production units in Finland, Turkey, and the United States. Trivitron is targeting revenue of ₹1,000 crore in FY27 and aims to significantly expand its business scale over the next five years.
Also Read: ESIC adds seven new healthcare facilities across india
Neuberg Diagnostics, launched in 2017, has emerged as a prominent player in advanced diagnostics, focusing on areas such as genomics, molecular diagnostics, digital pathology, and precision healthcare. Operating through an extensive network of nearly 250 laboratories across the country, the company reported revenues of approximately ₹1,600–1,700 crore in the previous financial year and is aiming to touch the ₹2,000 crore mark in FY27.
The planned IPOs reflect the growing investor interest in India’s healthcare sector, as companies across diagnostics, medical technology, hospitals, and specialty care continue to expand their reach and scale.
Like
Dislike
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!
